Results 41 to 50 of about 38,272 (314)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Frontiers in Pharmacology, 2022
Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood ...
Viktor Rotbain Curovic, Morten B. Houlind, Tine W. Hansen, Jesper Eugen-Olsen, Jens Christian Laursen, Mie K. Eickhoff, Frederik Persson, Peter Rossing, Peter Rossing   +8 more
doaj   +1 more source

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Cardiovascular Diabetology, 2022
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed. The mechanisms underlying
Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp, Richard G. IJzerman   +7 more
doaj   +1 more source

Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus [PDF]

, 2016
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus has not been established.
Cui, Wei, Fang, Zhenwei, Song, Yiqing, Tang, Huilin, Wang, Tiansheng, Zhai, Suodi   +5 more
core   +2 more sources

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]

, 2016
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes.Systematic review and meta-analysis.
A Berhan, A Lewin, A Liakos, A Patel, AK Singh, B Bode, B Bode, B Neal, B Zinman, C Mathieu, C Sonesson, C Triplitt, Cathy Bennett, CJ Bailey, CJ Bailey, CJ Bailey, CS Kovacs, CS Kovacs, D Moher, D Vasilakou, DS Shyangdan, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, F Zaccardi, Filip K. Knop, FJ Lavalle-Gonzalez, G Guyatt, G Musso, G Schernthaner, H Liu, H Storgaard, H Storgaard, Heidi Storgaard, HJ Lambers Heerspink, HU Haering, HU Haring, HU Haring, IM Stratton, J Bolinder, J Bolinder, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Yoon, JF List, JH Wu, JP Wilding, JP Wilding, JP Wilding, JP Wilding, K Damman, K Kaku, K Kaku, K Stenlof, K Stenlof, K Strojek, K Strojek, L Ji, L Merker, LA Leiter, LA Leiter, LA Leiter, Lise L. Gluud, M Laakso, M Ridderstrale, M Ridderstråle, M Roden, M Sarnak, MA Nauck, MA Nauck, Magnus F. Grøndahl, MH Ahmed, Mikkel B. Christensen, N Inagaki, Noel Christopher Barengo, O Ljunggren, P Gaede, P Jose, RA DeFronzo, RR Henry, RR Holman, S Del Prato, S Goring, S Kalra, S Matthaei, S Matthaei, S Ross, SA Jabbour, SE Inzucchi, SE Kahn, T Forst, T Kadowaki, Tina Vilsbøll, W Duckworth, WL Baker, WT Cefalu, WT Cefalu, Y Yilmaz   +103 more
core   +3 more sources

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [PDF]

, 2020
Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage.
Alves-Martinez, Pilar, Carranza-Naval, María José, García Alloza, Mónica, Herrera, Marta, Hierro Bujalance, Carmen, Infante-Garcia, Carmen, Lubián López, Simón Pedro, Marco González, Ángel José del, Suarez, Javier   +8 more
core   +1 more source

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes : systematic review and economic evaluation [PDF]

, 2017
Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose.
Clar, Christine, Clegg, Andrew, Colquitt, Jill, Court, Rachel A., Cummins, Ewen, Holt, Tim, Johnston, Rhona, McGrane, David, O'Hare, J. Paul, Royle, Pamela, Shantikumar, Saran, Tan, Bee K., Uthman, Olalekan A., Waugh, Norman   +13 more
core   +3 more sources

Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin

Heliyon, 2022
Based on recent clinical trials using sodium-glucose co-transporter 2 inhibitor (SGLT2i) demonstrating the significant improvement of outcomes of diabetic kidney disease (DKD), the paradigm shift from “glomerulocentric” to “tubule centric ...
Noriko Uehara-Watanabe, Natsuko Okuno-Ozeki, Itaru Nakamura, Tomohiro Nakata, Kunihiro Nakai, Aya Yagi-Tomita, Tomoharu Ida, Noriyuki Yamashita, Michitsugu Kamezaki, Yuhei Kirita, Satoaki Matoba, Keiichi Tamagaki, Tetsuro Kusaba   +12 more
doaj   +1 more source

Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index

Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) is a novel biomarker that serves as an indicator of coronary artery inflammation. Dapagliflozin has become an important component of standard treatment for type 2 diabetes because of its ...
Xuehua Liu, Tian Zhang, Rong Fu, Dan Liu, Jingyi Zhang, Qing Hu, Guangyao Song, Luping Ren   +7 more
doaj   +1 more source

Production, use, transfer of prodrug substances, and direct or indirect infringement of the patent: Focusing on the dapagliflozin formate case

Journal of Intellectual Property
This study explored whether the utilization of dapagliflozin formate, a dapagliflozin prodrug, constitutes direct (including literal infringement and infringement under the doctrine of equivalents) and indirect infringement, against a patent covering a ...
Kwanshik Kim
doaj   +1 more source

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors

Frontiers in Pharmacology, 2021
This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment.
Jong-Mi Seong, Jong Joo Kim, Hae Jin Kim, Hyun Soon Sohn   +3 more
doaj   +1 more source